GlassScriptPhysician profile
Michael B Mciver
NPI 1912386814
$5,477.00
in general payments reported to CMS, 2019-2025
25 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what 95% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $11.63 · 2021: $1,188 · 2022: $144 · 2023: $188 · 2024: $259 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579 · Travel and Lodging: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.69 |
| Travel and Lodging | $1,512.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,952.01 | 2021-2025 | General - Therapies, General - Pain Management, Wavewriter Alpha Prime 16 |
| Medtronic USA, INC. | $1,023.06 | 2019 | |
| Saluda Medical Americas, INC. | $470.34 | 2024-2025 | Evoke |
| Si-Bone, INC. | $391.67 | 2025 | |
| Merz Pharmaceuticals, LLC | $318.65 | 2022-2025 | Xeomin |
| Abbvie INC. | $190.73 | 2021-2025 | |
| Biogen, INC. | $140.82 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $136.80 | 2021 | |
| Stryker Corporation | $131.75 | 2021-2024 | Spinejack |
| Ucb, INC. | $131.72 | 2021 | |
| Spinal Simplicity, LLC | $129.69 | 2023-2025 | Ha Minuteman G3-R |
| Amgen INC. | $111.80 | 2021 | |
| Allergan, INC. | $83.84 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $55.64 | 2023-2024 | Dysport |
| Emd Serono, INC. | $34.34 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $25.32 | 2021 | |
| Abiomed | $21.33 | 2022 | |
| Merz North America, INC. | $19.01 | 2019 | |
| Bioventus LLC | $18.09 | 2024 | Durolane |
| Medtronic, INC. | $17.80 | 2025 | Synchromedii |
| Pacira Pharmaceuticals Incorporated | $17.50 | 2023 | Iovera, Zilretta |
| Janssen Pharmaceuticals, INC | $15.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.64 | 2021 | |
| Lilly USA, LLC | $13.03 | 2021 | |
| Currax Pharmaceuticals LLC | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mciver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.